Pramipexole and relapse of stimulants abuse
- Conditions
- Addiction.Other psychoactive substance related disorders
- Registration Number
- IRCT20190315043060N1
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
1- Patients who have administered stimulants (i.g. methamphetamine) at least 2 days in the past month.
2- Patients who have negative urine analysis for other addictive substances or the history of co-administration of drugs of abuse for no less than 3 weeks ago
3- Patients who meet the criteria of DSM-V for substance use disorder.
4- Patients who have failed to reduce or abstain currently abused substance at least for 2 times.
5- Patients who are seeking treatment and willing to abstain.
6- Age between 18 to 65 years
7- Patients who provide written informed consent.
8- Patients who have interest and are able to take part in a 4-month treatment phase and a 3-month follow up phase study (overall of 7 months).
9- Patients are only allowed to use pain killers, drugs used for neuropathic pain (gabapentin or pregabaline), and sleep aids (only benzodiazepines and Z-drugs)
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pramipexole's possible effects in reducing relapse of stimulants. Timepoint: 1st, 3rd, 6th month of the study and 2 periods of random sampling. Method of measurement: Questionnaires, Urine samples, Self report.
- Secondary Outcome Measures
Name Time Method